Financial Performance - The company achieved operating revenue of CNY 310,340,133.74, representing a year-on-year increase of 27.81%[2] - The total profit amounted to CNY 28,179,220.52, reflecting a growth of 68.16% compared to the previous year[2] - Net profit attributable to shareholders reached CNY 23,599,264.69, up 41.56% year-on-year[2] - The net profit after deducting non-recurring gains and losses was CNY 21,763,157.97, an increase of 57.98% from the previous year[2] - Basic earnings per share increased to CNY 0.31, a rise of 40.91% compared to the same period last year[2] Assets and Equity - Total assets at the end of the reporting period were CNY 514,790,732.40, up 13.62% from the beginning of the period[2] - Shareholders' equity attributable to the company was CNY 414,412,890.83, an increase of 5.39% from the beginning of the period[2] Market Expansion and Product Development - The company successfully expanded its domestic and international markets, contributing significantly to revenue growth[4] - New product developments, particularly in the food additive sector, have helped drive net profit growth[4] Cautionary Notes - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[5]
欧康医药(833230) - 2024 Q4 - 年度业绩